AT 1001 is a high-affinity and selective antagonist of the α3β4 nicotinic acetylcholine receptor ( α3β4 nAChR ) ( K i =2.64 nM). AT 1001 reversibly blocks inward currents induced by Epibatidine in HEK cells transfected with α3β4 nAChR. AT-1001 dose-dependently inhibits nicotine self-administration behavior in rats without affecting food-reinforced responding. AT 1001 can be utilized in the research of nicotine addiction and smoking cessation therapies.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.